|
|
Post by casualinvestor on Nov 10, 2015 15:49:30 GMT
On the positive side, I always swore to myself that the money made here wouldn't change me. I'm feeling pretty confident about sticking to that today  |
|
|
|
Post by actcfan on Nov 10, 2015 15:50:13 GMT
I wonder how many options at $4 and change went out after this S8 before this deal at $8.50?  |
|
|
|
Post by JHam on Nov 10, 2015 16:02:45 GMT
If the prior statements about big pharma knowing what OCAT was doing, and the partnering hints, and the value of the IP is real... we should see better offers from US companies. I will be surprised/disappointed if this IP goes to Japan. Common bidding war! This is peanuts! jak, I hate to break it to you, but if that is the case it would have already been one of those "better offers" from a US company that would have inked the deal. |
|
|
|
Post by JHam on Nov 10, 2015 16:04:33 GMT
Congrats! What was your average? |
|
|
|
Post by elk on Nov 10, 2015 16:06:37 GMT
If the prior statements about big pharma knowing what OCAT was doing, and the partnering hints, and the value of the IP is real... we should see better offers from US companies. I will be surprised/disappointed if this IP goes to Japan. Common bidding war! This is peanuts! Let's hope so. Astellas shareholders seem to think they have a good deal here; ALPMY is up $0.21 to $14.56 on the buyout. |
|
|
|
Post by JHam on Nov 10, 2015 16:12:07 GMT
More from stemdynasty:
I'm certain that 8.50 won't fly when retail owns 70% of the company. A cure forblindness, lupus, MS, Crohn's, uveitis, blood,platelets. It won't fly.
A cure? How many of these indications have ever been tested in humans? That's right. Zero. He should be happy they were able to eek out $379M imo.
|
|
|
|
Post by elk on Nov 10, 2015 16:28:36 GMT
More from stemdynasty: I'm certain that 8.50 won't fly when retail owns 70% of the company. A cure forblindness, lupus, MS, Crohn's, uveitis, blood,platelets. It won't fly.
A cure? How many of these indications have ever been tested in humans? That's right. Zero. He should be happy they were able to eek out $379M imo. OK, JHam, but highly promising potential cures would seem to be worth more than 8.50. |
|
|
|
Post by lcd on Nov 10, 2015 16:30:23 GMT
I haven't posted on this board in over 6 months but I have to agree with some other posters that this is the end of an era. I invested in a couple of other startup biotechs before ACTC/OCAT but they were definitely the company that really got me interested in biotech and investing. I lost a decent chunk of money on them in the years since my initial investment in 2008 but it was part of my tuition. I sold most of my holdings over the last two years but will get a small refund on my remaining tuition soon.
|
|
|
|
Post by JHam on Nov 10, 2015 16:37:06 GMT
More from stemdynasty: I'm certain that 8.50 won't fly when retail owns 70% of the company. A cure forblindness, lupus, MS, Crohn's, uveitis, blood,platelets. It won't fly.
A cure? How many of these indications have ever been tested in humans? That's right. Zero. He should be happy they were able to eek out $379M imo. OK, JHam, but highly promising potential cures would seem to be worth more than 8.50. I definitely disagree. Everything is "promising" in the pre-clinical stage. That does mean it is worth anything. |
|
|
|
Post by actcfan on Nov 10, 2015 16:48:07 GMT
OK, JHam, but highly promising potential cures would seem to be worth more than 8.50. I definitely disagree. Everything is "promising" in the pre-clinical stage. That does mean it is worth anything. I see (saw) more promise in OCAT than any other biotech I have looked at so I understand the point of POTENTIAL value left on the table and agree with it. That said it is CURRENTLY worth what its been trading at or what someone will pay for it. Management past and present destroyed so much (current and future) value by not being able to execute and bring these technologies closer to fruition. I still hold a strong belief in the idea of what this science is and the patents and approach OCAT was taking. But now its value is what it is - and it is a product of the people who ran it so poorly. |
|
|
|
Post by JHam on Nov 10, 2015 16:56:38 GMT
|
|
|
|
Post by tacomafunk on Nov 10, 2015 17:00:13 GMT
|
|
|
|
Post by goldencoin9999 on Nov 10, 2015 17:30:18 GMT
Thanks for this. I am considering requesting information from them. I want to understand why sell out for under $400 Millions. |
|
|
|
Post by greatceasarsghost on Nov 10, 2015 17:51:43 GMT
Merger? Its a buyout. This new company can do whatever it wants with the IP. Am I right about that or just whistling Dixie? |
|
|
|
Post by greatceasarsghost on Nov 10, 2015 17:54:34 GMT
I definitely disagree. Everything is "promising" in the pre-clinical stage. That does mean it is worth anything. I see (saw) more promise in OCAT than any other biotech I have looked at so I understand the point of POTENTIAL value left on the table and agree with it. That said it is CURRENTLY worth what its been trading at or what someone will pay for it. Management past and present destroyed so much (current and future) value by not being able to execute and bring these technologies closer to fruition. I still hold a strong belief in the idea of what this science is and the patents and approach OCAT was taking. But now its value is what it is - and it is a product of the people who ran it so poorly. Billions my friend, Billions were left. |
|
|
|
Post by CM kipper007 on Nov 10, 2015 17:58:53 GMT
After making 37% on this I have to say I am gutted. How can that be?
My wife makes the most delicious stew in the slow cooker. She just throws a bunch of ingredients in, does a little mixing and several hours later I am eating a feast.
Ocat was my slow cooker. I was waiting until this was ripe, but I feel like we had a power cut half way through. It is ok to eat, but more time would have made things perfect.
Balls.
|
|
|
|
Post by tacomafunk on Nov 10, 2015 18:02:17 GMT
I'm kind of surprised we haven't seen a PR or anything from Ocata themselves, yet.
Lanza quote is meaningless. total non-statement.
|
|
|
|
Post by CM kipper007 on Nov 10, 2015 18:07:30 GMT
I really am a bit lost at what to do now. Do I hold out and see what happens? If I do that, could I end up losing the $8.50? From the documents I read, it seems like this is a done deal with regards to management. I feel Paul was doing this deal for quite a while and this is the reason why p2 is a non-starter for both AMD and SMD. Dr Lanza forgets about the retail investors keeping him tied with his IP. And with management's massive share count in addition to the institutional shares that will go along with management, they swamp us little guys. So what can change now? The only thing I can see happening is another company tries to gazump Astellas, but I feel we have probably been showcased to the other big companies. This will also trigger a capital gains tax  |
|
|
|
Post by ignorantsilver on Nov 10, 2015 18:11:51 GMT
Ocata never stood a chance against the FDA. If you are a US citizen and ever voted democrat or republican, then pat yourselves on the back.
|
|
|
|
Post by iamaverb on Nov 10, 2015 18:12:08 GMT
We do have a fairly rabid shareholder base, and once the tender offers are delivered to the shareholders, and depending on response, there might be the possibility of Astellas having to raise their price in order to insure success. As far as other BP offers, I am quite sure Paul has shopped the company around for some time, but one can wish and hope for competitive bids once the fear of loss and hope to gain emotions kick in.
Fortune favors the brave, and I took full advantage of buying aggressively and on margin the few times the company fell into the 3's. Between my accounts and what I hold for my girls, we are a little over 80k shares, at an average price just north of $5. I am lucky enough to be profiting well into the six figures, but after the 9 years, time wasted and margin cost to get here, I am still an unhappy camper.
|
|
